Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study
Authors:
- Elsa ReallonERElsa Reallon
- MEMORA groupMGMEMORA group
- Zaza MakaroffZMZaza Makaroff
- Marie-Hélène CosteMCMarie-Hélène Coste
- Sophie DautricourtSDSophie Dautricourt
Open Access
- 23 July 2024
- journal article
- research article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 16 (1) , 1-7
Abstract
Background: Long-term exposure to anticholinergic and sedative drugs could be a modifiable risk factor for cognitive decline. The objective of this study was to measure the association between previous cumulative anticholinergic and sedative drug exposure (Drug Burden Index) and cognitive decline. Methods: A cohort study (MEMORA cohort) was conducted in a French memory clinic for patients attending a consultation between November 2014 and December 2020, with at least 2 Mini-Mental State Examination (MMSE) measurements (≥ 6 months apart) and available medication data from the local Primary Health Insurance Fund database (n = 1,970). Drug Burden Index was linearly cumulated until each MMSE measurement and was used to categorise patients according to their level of exposure (no exposure, moderate, or high). The longitudinal association between Drug Burden Index and MMSE was assessed using a multivariate linear mixed model, adjusted for age, education level, anxiety disorders, depressive disorders, functional autonomy, and behavioural disorders. Results: Overall, 1,970 patients were included with a mean follow-up duration of 2.78 years (± 1.54) and 2.99 visits per patients (5,900 MMSE + Drug Burden Index measurements collected). At baseline, 68.0% of patients had moderate cumulative anticholinergic and sedative drug exposure and a mean MMSE of 21.1. MMSE decrease was steeper in patients with moderate and high Drug Burden Index ( -1.74 and -1.70/year, respectively) than in patients with no exposure (-1.26/year) after adjusting for age, education, anxiety and depressive disorders, functional autonomy, and behavioural disorders (p < 0.01). Conclusions: Long-term exposure to anticholinergic and sedative drugs is associated with steeper cognitive decline. Medication review focusing on de-prescribing these drugs could be implemented early to reduce cognitive impairment.Keywords
This publication has 44 references indexed in Scilit:
- Methodological Challenges in Determining Longitudinal Associations Between Anticholinergic Drug Use and Incident Cognitive DeclineJournal of the American Geriatrics Society, 2014
- A Standard International Version of the Drug Burden Index for Cross‐National Comparison of the Functional Burden of Medications in Older PeopleJournal of the American Geriatrics Society, 2013
- Systematic review of anticholinergic risk scales in older adultsEuropean Journal of Clinical Pharmacology, 2013
- The cognitive impact of anticholinergics: A clinical reviewClinical Interventions in Aging, 2009
- Natural History of Decline in Instrumental Activities of Daily Living Performance over the 10 Years Preceding the Clinical Diagnosis of Dementia: A Prospective Population‐Based StudyJournal of the American Geriatrics Society, 2007
- A Drug Burden Index to Define the Functional Burden of Medications in Older PeopleArchives of internal medicine (1960), 2007
- Behavioural changes and psychological symptoms in dementia disordersThe Lancet Neurology, 2005
- Drug-Induced Cognitive Impairment in the ElderlyDrugs & Aging, 1999
- “Mini-mental state”Journal of Psychiatric Research, 1975
- Assessment of older people: self-maintaining and instrumental activities of daily living.1969